Exchange: NASDAQ·Updated 07:45 PM EDT
UNCY logo

UNCYUnicycive Therapeutics Inc

$5.36
$0.37
(6.46%)
Today
Closed $5.36
$0.04
(0.75%)
After Hours
Mkt Cap$152.99M
Vol2.09M
News
all
press releases
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
The law firm of Kirby McInerney LLP is investigating potential claims against Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ:UNCY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other...
Business Wire
News Placeholder
More News
News Placeholder
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval
Unicycive Therapeutics said on Tuesday that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate.
Stocktwits
News Placeholder
Why Is Unicycive Therapeutics Stock Falling Tuesday?
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again over third-party manufacturing issues.read more...
Benzinga
News Placeholder
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time?
Unicycive Therapeutics said it received a Complete Response Letter from the U.S. Food and Drug Administration due to previously identified deficiencies at a third-party manufacturing facility.
Stocktwits
News Placeholder
US Stocks Mixed; Home Prices Increase 1.1% In April
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up 0.09%. Edible Garden AG up 87%, Unicycive Therapeutics down 46%.read more...
Benzinga
News Placeholder
UNCY Stock Rallies 8% As Retail Traders Anticipate FDA Clearance For Lead Drug Candidate
Unicyive is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.
Stocktwits
News Placeholder
UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug
Unicyive Therapeutics is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat hyperphosphatemia in patients with chronic kidney disease on dialysis following a previous rejection.
Stocktwits
News Placeholder
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five...
MarketBeat
News Placeholder
Unicycive Therapeutics (NASDAQ:UNCY) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
B. Riley Financial Begins Coverage on Unicycive Therapeutics (NASDAQ:UNCY)
B. Riley Financial assumed coverage on shares of Unicycive Therapeutics in a report on Friday. They issued a "buy" rating and a $22.00 price target on the stock...
MarketBeat
<
1
2
...
>